Self Help Program for Hypnotics Withdrawal in Insomniac Patients (PROPERSOM)
Self-help Program for Hypnotics Withdrawal in Chronic Insomniac Patients: A Randomized Controlled Clinical Trial
Persistent insomnia has a high prevalence in French general population affecting between 15.8 % and 19 % of adults. In France, the disease is mainly managed by general practitioners (GP) who usually proposed intermediate half-life benzodiazepines and Z-drugs in first-line treatment. French Health authorities recommend restricting the consumption of both hypnotics to no more than 4 weeks, considering their potential adverse effects (memory impairment, altered sleep physiology, motor-vehicle crash), and the risk of tolerance and dependence. However, it appears that a majority of patients become chronic users. Therefore, discontinuation of benzodiazepines/Z-drugs is recommended, but it may appear as a challenge due to withdrawal symptoms and psychological factors (anticipatory anxiety, fear of rebound insomnia).
Numerous studies have shown that programs based on Cognitive-Behavioural Therapy (CBT) principles improve sleep and daily life quality leading to hypnotic taper and maintain of hypnotic abstinence in insomniac patients. Cognitive-Behavioural Therapy (CBT) is based on 4 components: sleep restriction, stimulus control, cognitive therapy and sleep hygiene education. This therapy is dependent on a therapeutic alliance between practitioner and patient. Unfortunately, there are an insufficient number of trained CBT experts especially in France.
The implementation of an internet-delivered self-help program based on time-in-bed restriction and stimulus control may be an issue within the context of general practice.
Online programs based on CBT principles have been proved to be effective in improving the sleep and daytime functioning in this population, but the studies were realized in small patients groups.
Investigators hypothesis is that a simple and internet-delivered short-term program based on sleep restriction therapy and stimulus control (following to a GP consultation) may facilitate hypnotics discontinuation (benzodiazepines/Z-drugs) in patient with insomnia disorder still reporting sleep complaints in comparison with a tapering alone (no access to the self-help program).
연구 개요
상태
정황
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Bordeaux, 프랑스, 33076
- CHU de Bordeaux
-
Garches, 프랑스, 92380
- APHP Hôpital Raymond Poincaré
-
Lille, 프랑스, 59037
- CHRU de Lille
-
Montpellier, 프랑스, 34295
- CHU de Montpellier
-
Paris, 프랑스, 75013
- AP-HP Hôpital Pitié-Salpêtrière
-
Paris, 프랑스, 75181
- APHP Hôtel-Dieu de Paris
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patient complaining of persistent insomnia without co-morbidities (DSM-5) and treated for at least 3 months with monotherapy of:
- Zopiclone or Zolpidem with usual doses (3.5 doses per week at least to a maximum of 14 per week) OR Intermediate half-life benzodiazepines included in the appendix 1 list with usual doses (3.5 doses per week at least to a maximum of 14 per week)
- Motivated to stop hypnotic treatment (score >5 on a 1 to 10 degrees VAS)
- 18 to 75 years old,
- Man or woman,
- Having an internet connection,
- Affiliated to a national health service,
- Having given written informed consent to participate in the trial.
Exclusion Criteria:
- Patient with 2 psychotropic drugs or more taken daily for insomnia complaints (antidepressant, anxiolytic and antihistamine treatments will be allowed if they are prescribed for a stabilized mood and/or anxiety disorder).
- Patient not believing in short-term simple self-help program
- Insomnia with comorbidities other than a stabilized mood and/or anxiety disorder
- Night and shift-workers,
- Current Psychiatric disorder : mood disorder (depression, bipolar disorder) with a BDI score > 19, anxiety disorder, psychosis
- All sleep disorders other than persistent insomnia (clinical interview),
- Progressive neurological diseases that include restless legs syndrome,
- Unstable Cardiovascular disease,
- Unstable respiratory or endocrinological diseases (clinical interview),
- Drug addiction, alcohol addiction during the previous 6 months (clinical interview),
- Having undertaken trans-meridian travel (± 3H) in the previous 1 month
- Pregnant or lactating woman,
- Current participation in psychotherapy.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Standardized hypnotic taper and self-help program
|
The gradual hypnotic taper is standardized and is adjusted depending on the hypnotic treatment and the initial weekly dose.
The practitioner will give to the patient a calendar for the taper period with the specific dose for each day (name of hypnotic, quantity and dose of pills).
The short-term simple self-help program consists in:
The restriction of time in bed would be delivered by an e-health tool (web site). The patient will have to connect to the web site with an individual connexion password. He will connect every day to complete an on-line sleep diary during the period of the simple short-term behavioural program (5 weeks). After this period, patients will have the choice to continue connecting to the website and using the program or to stop using the program. |
|
활성 비교기: Standardized hypnotic taper only
|
The gradual hypnotic taper is standardized and is adjusted depending on the hypnotic treatment and the initial weekly dose.
The practitioner will give to the patient a calendar for the taper period with the specific dose for each day (name of hypnotic, quantity and dose of pills).
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Urinary hypnotics screening assessed during Visit 2
기간: 7 weeks after randomization visit
|
Urine will be frozen and afterwards analysed by a central laboratory (Unité de biologie médicale multidisciplinaire, CHU Bordeaux) for hypnotics (benzodiazepines and Z-drugs) using Gas Chromatography-Mass Spectrometry.
|
7 weeks after randomization visit
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Urinary hypnotics screening assessed during Visit 3
기간: 17 weeks after randomization visit
|
Urine will be frozen and afterwards analysed by a central laboratory (Unité de biologie médicale multidisciplinaire, CHU Bordeaux) for hypnotics (benzodiazepines and Z-drugs) using Gas Chromatography-Mass Spectrometry.
|
17 weeks after randomization visit
|
|
Total sleep time obtained by actimetry
기간: During 10 nights before Visit 2 wich is scheduled 7 weeks after randomization visit
|
During 10 nights before Visit 2 wich is scheduled 7 weeks after randomization visit
|
|
|
Sleep efficiency obtained by actimetry
기간: During 10 nights before Visit 2 wich is scheduled 7 weeks after randomization visit
|
During 10 nights before Visit 2 wich is scheduled 7 weeks after randomization visit
|
|
|
Wake after sleep onset obtained by actimetry
기간: During 10 nights before Visit 2 wich is scheduled 7 weeks after randomization visit
|
During 10 nights before Visit 2 wich is scheduled 7 weeks after randomization visit
|
|
|
Sleep latency obtained by actimetry
기간: During 10 nights before Visit 2 wich is scheduled 7 weeks after randomization visit
|
During 10 nights before Visit 2 wich is scheduled 7 weeks after randomization visit
|
|
|
Total sleep time obtained by sleep diary
기간: Every night between Pre-Inclusion visit (Visit 0) and Week 5 after Visit 1
|
Every night between Pre-Inclusion visit (Visit 0) and Week 5 after Visit 1
|
|
|
Sleep efficiency obtained by sleep diary
기간: Every night between Pre-Inclusion visit (Visit 0) and Week 5 after Visit 1
|
Every night between Pre-Inclusion visit (Visit 0) and Week 5 after Visit 1
|
|
|
Wake after sleep onset obtained by sleep diary
기간: Every night between Pre-Inclusion visit (Visit 0) and Week 5 after Visit 1
|
Every night between Pre-Inclusion visit (Visit 0) and Week 5 after Visit 1
|
|
|
Sleep latency obtained by sleep diary
기간: Every night between Pre-Inclusion visit (Visit 0) and Week 5 after Visit 1
|
Every night between Pre-Inclusion visit (Visit 0) and Week 5 after Visit 1
|
|
|
Insomnia Severity Scale (ISI) score
기간: Pre-inclusion visit (between 21 to 10 days before randomization), randomization visit (Visit 1) ,7 weeks after randomization (Visit 2) and 17 weeks after randomization (Visit 3)
|
Pre-inclusion visit (between 21 to 10 days before randomization), randomization visit (Visit 1) ,7 weeks after randomization (Visit 2) and 17 weeks after randomization (Visit 3)
|
|
|
Leeds Sleep Evaluation Questionnaire (LSEQ) score
기간: 7 weeks after randomization (Visit 2) and 17 weeks after randomization (Visit 3)
|
7 weeks after randomization (Visit 2) and 17 weeks after randomization (Visit 3)
|
|
|
Beck Depression Inventory Second Edition (BDI-II) score
기간: Pre-inclusion visit (between 21 to 10 days before randomization), randomization visit (Visit 1) ,7 weeks after randomization (Visit 2) and 17 weeks after randomization (Visit 3)
|
Pre-inclusion visit (between 21 to 10 days before randomization), randomization visit (Visit 1) ,7 weeks after randomization (Visit 2) and 17 weeks after randomization (Visit 3)
|
|
|
Beck anxiety Inventory (BAI) score
기간: Pre-inclusion visit (between 21 to 10 days before randomization), randomization visit (Visit 1) ,7 weeks after randomization (Visit 2) and 17 weeks after randomization (Visit 3)
|
Pre-inclusion visit (between 21 to 10 days before randomization), randomization visit (Visit 1) ,7 weeks after randomization (Visit 2) and 17 weeks after randomization (Visit 3)
|
|
|
Short-Form SF-36 Health Survey score
기간: Pre-inclusion visit (between 21 to 10 days before randomization), randomization visit (Visit 1) ,7 weeks after randomization (Visit 2) and 17 weeks after randomization (Visit 3)
|
Pre-inclusion visit (between 21 to 10 days before randomization), randomization visit (Visit 1) ,7 weeks after randomization (Visit 2) and 17 weeks after randomization (Visit 3)
|
|
|
Benzodiazepine Withdrawal Symptoms Questionnaire (BWSQ) score
기간: 7 weeks after randomization (Visit 2) and 17 weeks after randomization (Visit 3)
|
7 weeks after randomization (Visit 2) and 17 weeks after randomization (Visit 3)
|
|
|
Self-efficiency visual analog scale score
기간: Pre-inclusion visit (between 21 to 10 days before randomization), randomization visit (Visit 1) and 7 weeks after randomization (Visit 2)
|
Pre-inclusion visit (between 21 to 10 days before randomization), randomization visit (Visit 1) and 7 weeks after randomization (Visit 2)
|
|
|
Reasons for non-compliance obtained during patient interview
기간: 7 weeks after randomization (Visit 2) and 17 weeks after randomization (Visit 3)
|
7 weeks after randomization (Visit 2) and 17 weeks after randomization (Visit 3)
|
공동 작업자 및 조사자
수사관
- 연구 의자: Antoine BENARD, MD-PhD, USMR - CHU de Bordeaux
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- CHUBX 2014/35
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .